Opportunity Information: Apply for CDC RFA CK 26 0230
The CDC (NCEZID) is soliciting applications under the cooperative agreement opportunity titled "Advancing Global Capacity to Detect and Respond to Fungal Diseases" (Funding Opportunity Number: CDC-RFA-CK-26-0230). The goal is to fund practical, sustainable work that strengthens how countries and regions detect, diagnose, track, and respond to fungal disease threats. The emphasis is on building systems that last: improving the public health infrastructure, developing the workforce, expanding laboratory and diagnostic capacity, and upgrading how data are collected and used so that public health decisions and rapid response actions are based on timely, reliable information.
The NOFO frames fungal diseases as a growing health security concern, especially pathogens that can spread internationally and those linked to antifungal resistance. Activities supported by this funding are meant to help countries manage and control priority fungal pathogens at the source, rather than relying on downstream responses after problems cross borders. In practice, that means creating or strengthening surveillance and reporting networks, improving specimen collection and laboratory confirmation, training personnel who can recognize and investigate fungal disease events, and putting data systems in place that translate lab and surveillance findings into public health action. The broader intended impact over time is a reduced global burden of fungal diseases, stronger national and regional preparedness, and lower risk to the United States through earlier detection and more effective containment of fungal threats abroad.
This opportunity aligns with the America First Global Health Strategy by focusing on country capacity and long-term ownership. The expectation is not just to run a project for the life of the award, but to integrate fungal disease detection and response functions into existing public health systems so that they continue after the grant ends. The CDC will provide technical guidance and help ensure alignment with legal and regulatory requirements, but recipients are expected to lead implementation and handle daily program management.
A key eligibility condition is demonstrated oversight capacity. Applicants must show they have the institutional systems and expertise to manage both the technical work and the financial side responsibly. The applicant organization itself, not a third party or sub-recipient, must be the primary lead and remain fully accountable for programmatic results and financial performance. That includes directing and monitoring interventions, managing budgets, tracking expenditures, meeting compliance obligations, and completing required financial and performance reporting.
The NOFO also makes it clear that responsiveness to application requirements is a gating issue. Applications will be deemed non-responsive and removed from consideration if required documents are missing or if the funding request exceeds $300,000. Submissions that do not follow the stated formatting, content, and documentation instructions can also be rejected without review, so careful compliance with the application checklist and limits is essential.
In terms of basic program mechanics, the award instrument is a cooperative agreement, the activity category is health, and the CFDA number is 93.318. The eligible applicant pool is broad and includes various levels of government (state, county, city/township, special districts), public and private institutions of higher education, federally recognized tribal governments and other tribal organizations, public housing authorities/Indian housing authorities, nonprofits (both 501(c)(3) and non-501(c)(3)), and for-profit entities (including small businesses). The CDC anticipates making about 10 awards. The posted closing date is 2026-08-31. The listing shows an award ceiling of 0, which typically indicates that a specific ceiling is not provided in that field, but the NOFO text explicitly notes that requests above $300,000 will be considered non-responsive, effectively functioning as a strict cap for application purposes.Apply for CDC RFA CK 26 0230
- The Centers for Disease Control - NCEZID in the health sector is offering a public funding opportunity titled "Advancing Global Capacity to Detect and Respond to Fungal Diseases" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.318.
- This funding opportunity was created on 2026-07-30.
- Applicants must submit their applications by 2026-08-31. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 10 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
1) What is this funding opportunity?
This is a CDC (NCEZID) cooperative agreement funding opportunity titled "Advancing Global Capacity to Detect and Respond to Fungal Diseases" (Funding Opportunity Number: CDC-RFA-CK-26-0230). It supports practical, sustainable work to strengthen how countries and regions detect, diagnose, track, and respond to fungal disease threats.
2) What is the overall goal of the program?
The goal is to build lasting country and regional capacity to manage fungal disease threats by strengthening public health infrastructure, developing the workforce, expanding laboratory and diagnostic capacity, and improving data collection and use so decisions and response actions are based on timely, reliable information.
3) Why is CDC focusing on fungal diseases in this NOFO?
The NOFO frames fungal diseases as a growing health security concern, especially pathogens that can spread internationally and those linked to antifungal resistance. The intent is to support earlier detection and more effective containment of fungal threats abroad, reducing risk to the United States and lowering the global burden over time.
4) What types of activities does the funding support?
Supported activities include creating or strengthening surveillance and reporting networks, improving specimen collection and laboratory confirmation, training personnel to recognize and investigate fungal disease events, and implementing data systems that translate laboratory and surveillance findings into public health action.
5) What does "building systems that last" mean in this opportunity?
The emphasis is on integrating fungal disease detection and response functions into existing public health systems so they continue after the grant ends. The expectation is not to run a standalone project for the award period, but to strengthen core systems, workforce, labs, and data practices in a way that becomes part of routine operations.
6) What is meant by addressing threats "at the source"?
The NOFO emphasizes helping countries manage and control priority fungal pathogens where they emerge, rather than relying on downstream responses after problems cross borders. In practice, this is reflected in investments in surveillance, diagnostics, reporting, investigation capacity, and data-to-action workflows.
7) What is the funding instrument?
The award instrument is a cooperative agreement. This means CDC will provide technical guidance and support alignment with legal and regulatory requirements, while the recipient leads implementation and handles day-to-day program management.
8) Who is expected to lead the work day to day?
Recipients are expected to lead implementation and handle daily program management. CDC’s role is described as providing technical guidance and ensuring alignment with legal and regulatory requirements.
9) What are the eligible applicant types?
The eligible applicant pool is broad and includes:
- Government organizations (state, county, city/township, and special districts)
- Public and private institutions of higher education
- Federally recognized tribal governments and other tribal organizations
- Public housing authorities / Indian housing authorities
- Nonprofits (501(c)(3) and non-501(c)(3))
- For-profit entities (including small businesses)
10) How many awards does CDC expect to make?
CDC anticipates making about 10 awards.
11) What is the application deadline?
The posted closing date is 2026-08-31.
12) What is the maximum amount an applicant can request?
The NOFO text states that applications will be deemed non-responsive and removed from consideration if the funding request exceeds $300,000. Even though the listing shows an award ceiling of 0 (often indicating the ceiling is not provided in that specific field), the $300,000 limit functions as a strict cap for application purposes based on the NOFO language provided.
13) What happens if an application requests more than $300,000?
It will be deemed non-responsive and removed from consideration.
14) What does "non-responsive" mean in this NOFO?
In this context, "non-responsive" means the application is removed from consideration. The information provided states this can occur if required documents are missing, if the funding request exceeds $300,000, or if the submission does not follow stated formatting, content, and documentation instructions.
15) Are formatting and documentation requirements important?
Yes. The NOFO indicates that submissions that do not follow stated formatting, content, and documentation instructions can be rejected without review. Careful compliance with the application checklist and limits is described as essential.
16) What is the key eligibility condition highlighted in the NOFO?
A key eligibility condition is demonstrated oversight capacity. Applicants must show they have the institutional systems and expertise to manage both the technical work and the financial side responsibly.
17) Can a sub-recipient or third party be the primary lead?
No. The applicant organization itself must be the primary lead and remain fully accountable for programmatic results and financial performance. The NOFO language provided specifies that the applicant cannot shift primary responsibility to a third party or sub-recipient.
18) What does the applicant need to be accountable for?
The applicant must be accountable for both programmatic results and financial performance. This includes directing and monitoring interventions, managing budgets, tracking expenditures, meeting compliance obligations, and completing required financial and performance reporting.
19) What kinds of capacity-building areas are emphasized?
The opportunity emphasizes strengthening:
- Public health infrastructure
- Workforce development
- Laboratory and diagnostic capacity
- Data collection, reporting, and use (so lab and surveillance findings translate into public health action)
20) What is the activity category and CFDA number?
The activity category is health, and the CFDA number is 93.318.
21) How does this opportunity connect to broader strategy?
The opportunity aligns with the America First Global Health Strategy by focusing on country capacity and long-term ownership, with an emphasis on integrating fungal disease functions into existing systems so they persist after the award period.
22) What is the intended long-term impact?
The intended impact over time is a reduced global burden of fungal diseases, stronger national and regional preparedness, and lower risk to the United States through earlier detection and more effective containment of fungal threats abroad.
23) What are examples of "data-to-action" improvements mentioned?
The NOFO description emphasizes upgrading how data are collected and used so public health decisions and rapid response actions are based on timely, reliable information, including putting data systems in place that translate lab and surveillance findings into public health action.
24) What should applicants pay closest attention to when preparing an application?
Based on the information provided, applicants should pay close attention to: (1) staying at or under the $300,000 request limit; (2) including all required documents; and (3) following formatting, content, and documentation instructions to avoid being deemed non-responsive and removed from consideration.
Browse more opportunities from the same category: Health
Previous opportunity: FY 2026 DRUG COURT TRAINING AND TECHNICAL ASSISTANCE COMPETITIVE COOPERATIVE AGREEMENT SOLICITATION
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for CDC RFA CK 26 0230
Applicants also applied for:
Applicants who have applied for this opportunity (CDC RFA CK 26 0230) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pediatric Disaster Care Centers of Excellence Program Cooperative Agreement Apply for EP U3R 26 001 Funding Number: EP U3R 26 001 Agency: Assistant Secretary for Preparedness and Response Category: Health Funding Amount: Case Dependent |
| Healthy Cooking in Communities Apply for HP DPH 26 001 Funding Number: HP DPH 26 001 Agency: Office of the Assistant Secretary for Health Category: Health Funding Amount: $10,000,000 |
| Applied Drug Policy Research Experiences Apply for RD AL RDAAL 26 001 Funding Number: RD AL RDAAL 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $100,000 |
| Nonfatal Overdoses in Emergency Departments: Bridging Patient Characteristics, Biospecimen Toxicology, and Drug Supply Composition Apply for EDS EDS 26 001 Funding Number: EDS EDS 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $500,000 |
| Improving The Capacity of Tribal Communities to Identify Emerging Drug Threats Apply for RD ET RDA 26 001 Funding Number: RD ET RDA 26 001 Agency: Office of National Drug Control Policy Category: Health Funding Amount: $300,000 |
| Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed) Apply for RFA AG 27 010 Funding Number: RFA AG 27 010 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Grants for Early Medical/Surgical Specialists' Transition to Aging Research (GEMSSTAR) (R03 Clinical Trial Optional) Apply for PAR 27 096 Funding Number: PAR 27 096 Agency: National Institutes of Health Category: Health Funding Amount: $125,000 |
| BRAIN Initiative: Integrative Team-Research BRAIN Circuits Program - iBCP (RM1 Clinical Trial Not Allowed) Apply for RFA NS 27 002 Funding Number: RFA NS 27 002 Agency: National Institutes of Health Category: Health Funding Amount: $8,000,000 |
| Cancer Advancement through Partnerships in Research and Infrastructure (CAPRI) (U54 Clinical Trial Optional) Apply for PAR 28 062 Funding Number: PAR 28 062 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required) Apply for PAR 27 065 Funding Number: PAR 27 065 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required) Apply for RFA DK 27 139 Funding Number: RFA DK 27 139 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIH Brain Development Cohorts (NBDC) and Population Assessment of Tobacco and Health (PATH) Study Biospecimen Access (X01 Clinical Trial Not Allowed) Apply for PAR 27 051 Funding Number: PAR 27 051 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Silvio O. Conte Centers for Basic Neuroscience or Translational Mental Health Research (P50 Clinical Trial Optional) Apply for PAR 27 127 Funding Number: PAR 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required) Apply for RFA CA 27 005 Funding Number: RFA CA 27 005 Agency: National Institutes of Health Category: Health Funding Amount: $700,000 |
| Limited Competition: Centers of Biomedical Research Excellence: Development Phase (COBRE-D) (P30 - Clinical Trial Not Allowed) Apply for PAR 27 054 Funding Number: PAR 27 054 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Clinical Centers (U01 Clinical Trial Required) Apply for RFA DK 27 125 Funding Number: RFA DK 27 125 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cooperative Centers for Experimental Hematology (CCEHs) (U54- Clinical Trial Not Allowed) Apply for RFA DK 27 127 Funding Number: RFA DK 27 127 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) Apply for RFA AI 27 002 Funding Number: RFA AI 27 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) Apply for PAR 27 056 Funding Number: PAR 27 056 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Paul B. Beeson Emerging Leaders Career Development Award in Aging (K76 Clinical Trial Not Allowed) Apply for PAR 27 112 Funding Number: PAR 27 112 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "CDC RFA CK 26 0230", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.